Neural degeneration and the transport of neurotransmitters

Annals of Neurology

Volumn 34, Issue 5, 1993, Pages 638-645

  Edwards, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NEUROTRANSMITTER;

CELL MEMBRANE TRANSPORT; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; HUMAN; MOLECULAR CLONING; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; BIOLOGICAL TRANSPORT; CELL MEMBRANE; HUMAN; NERVE DEGENERATION; NEUROTRANSMITTERS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 0027451155     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410340504     Document Type: Article

References (87)

1. Alzheimer's disease: a disorder of central cholinergic innervation
2. Chronic parkinsonism in humans due to a product of meperidine analog synthesis
3. Selective nigral toxicity after systemic administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in the monkey
4. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the rat
5. Sites of the neurotoxic action of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus
6. 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
7. Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys
8. Dose‐dependent destruction of the coeruleus‐cortical and nigral‐striatal projections by MPTP
9. Intraneuronal generation of a pyridinium metabolite may cause drug‐induced parkinsonim
10. Pargyline prevents MPTP‐induced parkinsonism in primates
11. Protection against the dopaminergic neurotoxicity of 1‐methyl‐4‐phenyl‐1,2,5,6‐tetrahydropyridine by monoamine oxidase inhibitors
12. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
13. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem
14. Parkinsonism‐inducing neurotoxin, N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine: uptake of the metabolite N‐methyl‐4‐phenylpyridine by dopamine neurons explains selective toxicity
15. Energy‐dependent uptake of n‐methyl‐4‐phenylpyridinium, the neurotoxic metabolite of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine, by mitochondria
16. +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase
17. +) involves binding at the same site as the respiratory inhibitor, rotenone
18. Inhibition of NADH‐linked oxidation in brain mitochondria by 1‐methyl‐4‐phenylpyridine, a metabolite of the neurotoxin 1‐methyl‐1,2,3,6‐tetrahydropyridine
19. Irreversible inhibition of mitochondrial complex I by 1‐methyl‐4‐phenylpyridinium: evidence for free radical involvement
20. Mechanisms of storage and transport of neurotransmitters
21. Cloning and expression of a rat brain GABA transporter
22. Expression cloning of a cocaine‐ and antidepressant‐sensitive human noradrenaline transporter
23. Cloning and expression of a cocaine‐sensitive rat dopamine transporter
24. Cloning and expression of a cocaine‐sensitive dopamine transporter complimentary DNA
25. Bertrand L, Caron MG. Cloning and functional characterization of a cocaine‐sensitive dopamine transporter
26. Cloning of a serotonin transporter affected by antidepressants
27. Cloning and expression of a functional serotonin transporter from rat brain
28. Molecular cloning and expression of a high affinity L‐proline transporter expressed in putative glutamatergic pathways of rat brain
29. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors
30. Cloning, expression and localization of a rat brain high‐affinity glycine transporter
31. Functional expression and CNS distribution of a beta‐alanine‐sensitive neuronal GABA transporter
32. Lac permease of Escherichia coli: topology and sequence elements promoting membrane insertion
33. +: uptake and toxicity in noneuronal COS cells expressing dopamine transporter cDNA
34. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
35. Dopamine transporter mRNA: dense expression in ventral midbrain neurons
36. Neurochemical and behavioral effects of systemic and intranigral administration of N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the rat
37. Selective lesion of nigrostriatal neurons by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys
38. Repeated administration of N‐methyl‐4‐phenyl‐1,2,5,6‐tetrahydropyridine to rats is not toxic to striatal dopamine neurons
39. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects
40. Strain differences in systemic 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood‐brain barrier
41. Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the brain and blood‐brain barrier in vitro in five rat strains
42. Correlation between the neostriatal content of the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration to several strains of mice
43. Studies on the effect of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice
44. Mechanisms of toxicity and cellular resistance to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine and 1‐methyl‐4‐phenylpyridinium in adrenomedullary chromaffin cell cultures
45. Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells
46. A dopaminergic cell line variant resistant to the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
47. +
48. Subcellular compartmentalization of 1‐methyl‐4‐phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells
49. Energy‐driven uptake of the neurotoxin 1‐methyl‐4‐phenylpyridinium into chromaffin granules via the catecholamine transporter
50. + toxicity encodes a vesicular amine transporter
51. The transport of neurotransmitters into synaptic vesicles
52. Cellular and molecular biology of the presynaptic nerve terminal
53. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport
54. + pumping into intracellular organelles
55. Structure and function of vacuolar class of ATP‐driven proton pumps
56. Expression cloning of a reserpine‐sensitive vesicular monoamine transporter
57. Nucleotide sequence analysis reveals similarities between proteins determining methylenomycin A resistance in streptomyces and tetracycline resistance in enbacteria
58. Efflux‐mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system
59. Energetics of tetracyline efflux system encoded by Tn10 in Escherichia coli
60. Energetics of tetracycline efflux system encoded by Tn10 in Escherichia coli
61. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action
62. The molecular mechanism of “ectasy” [3,4,‐methylenedioxymethamphetamin (MDMA)]: serotonin transporters are targets for MDMA‐induced serotonin release
63. Catecholamine toxicity in cerebral cortex in dissociated cell culture
64. Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
65. Monoamine oxidase and oxidative stress at dopaminergic synapses
66. Do environmental toxins cause Parkinson's disease? A critical review
67. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it
68. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease
69. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
70. Evidence for neuromelanin involvement in MPTP‐induced neurotoxicity
71. Mitochondrial respiratory inhibition by N‐methylated beta‐carboline derivatives structurally resembling N‐methyl‐4‐phenylpyridine
72. Mono‐N‐methylation of 1,2,3,4‐tetrahydro‐beta‐carbolines in brain cystol: absence of indole methylation
73. Novel S‐adenosylmethionine‐dependent indole‐N‐methylation of beta‐carbolines in brain particulate fractions
74. Twin studies and the genetics of Parkinson's disease—a reappraisal
75. A large kindred with autosomal dominant Parkinson's disease
76. Cloning, pharmacological characterization and chromosome assignment of the human dopamine transporter
77. Human dopamine transporter gene (DATI) maps tochromosome 5p15.3 and displays a VNTR
78. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis
79. Glutamate neurotoxicity and disease of the nervous system
80. Primary structure and functional characterization of a high‐affinity glutamate transporter
81. Cloning and expression of a rat brain L‐glutamate transporter
82. +‐dependent glutamate/aspartate transporter from rat brain
83. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrohic lateral sclerosis
84. Transgenic mice with increased Cu/Zn‐superoxide dismutase activity are resistant to N‐methyl‐4‐phenyl‐1,2,5,6‐tetrahydropyridine‐induced neurotoxicity
85. Role for excitatory amino acids in methamphetamine‐induced nigrostriatal dopaminergic toxicity
86. + neurotoxicity by N‐methyl‐D‐asparate antagonists